CIK 0001512762 · Accelerated filer<br>Smaller reporting company
Coherus Oncology, Inc.
Sign in to watch- Ticker
- CHRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273615821
- Phone
- (650) 649-3530
- Business address
- C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA, 94065
- Former names
- Coherus BioSciences, Inc., BioGenerics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-01-25 | Viret Jean-Frederic Chief Financial Officer | Sale | −6,144 | $19.00 | $117K | 61,295 |
| 2021-01-25 | Viret Jean-Frederic Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −40,000 | 61,569 | ||
| 2021-01-23 | Lanfear Dennis M President & CEO | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2021-01-19 | Anicetti Vincent R Chief Operating Officer | Option exercise | +2,500 | $2.50 | $6K | 62,239 |
| 2021-01-19 | Anicetti Vincent R Chief Operating Officer | Sale | −2,500 | $17.94 | $45K | 59,739 |
| 2021-01-19 | Anicetti Vincent R Chief Operating Officer | Option exercise · Stock Option (Right to Buy) | −2,500 | 2,488 | ||
| 2021-01-11 | Wahlstrom Mats Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2021-01-11 | HEALY JAMES Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2021-01-11 | Szela Mary T Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2021-01-11 | TZOUMAKAS KIMBERLY JO Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2021-01-11 | NUSSBAUM SAMUEL R MD Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2021-01-11 | LAWLIS V BRYAN Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2021-01-11 | Vexler Vladimir Chief Scientific Officer | Grant or award | +31,250 | 65,146 | ||
| 2021-01-11 | Vexler Vladimir Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +62,500 | 62,500 | ||
| 2021-01-11 | Viret Jean-Frederic Chief Financial Officer | Grant or award | +31,250 | 67,439 | ||
| 2021-01-11 | Viret Jean-Frederic Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +62,500 | 62,500 | ||
| 2021-01-11 | Anicetti Vincent R Chief Operating Officer | Grant or award | +31,250 | 59,739 | ||
| 2021-01-11 | Anicetti Vincent R Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +62,500 | 62,500 | ||
| 2021-01-10 | Vexler Vladimir Chief Scientific Officer | Shares withheld for taxes | −4,080 | $18.18 | $74K | 33,896 |
| 2021-01-10 | Viret Jean-Frederic Chief Financial Officer | Shares withheld for taxes | −4,080 | $18.18 | $74K | 36,189 |
Page 11 of 39 · 768 trades